



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/720,380	12/20/2000	Hassan Jomaa	12964.18	2374

7590

03/15/2002

Warren B Kice
Haynes and Bonne
901 Main Street Suite 3100
Dallas, TX 75202

EXAMINER

CLARDY, S

ART UNIT

PAPER NUMBER

1616

DATE MAILED: 03/15/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.
09/720,380

Applicant(s)
Jomaa

Examiner
S. Mark Clardy

Art Unit
1616



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on Dec 20, 2000.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-23 is/are pending in the application.
- 4a) Of the above, claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) _____ is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claims 1-23 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are objected to by the Examiner.
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

- 13) ☒ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
- a) ☒ All b) ☐ Some* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- *See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

- 15) ☐ Notice of References Cited (PTO-892) 18) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 16) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 19) ☐ Notice of Informal Patent Application (PTO-152)
- 17) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____ 20) ☐ Other:

Art Unit: 1616

Claims 1-23 are pending in this application which has been filed under 35 USC 371 as a national stage application of PCT/EP99/04260, filed June 23, 1999. This application lacks unity of invention under 37 CFR 1.475 (MPEP 1850, 1893.03(d)).

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-2, drawn to compositions comprising:

- A. an anti-infectious active agent that inhibits the 2C-methylerythrose-4-metabolic pathway
- B. a lipid metabolism inhibitor.

Group II, claim 3, drawn to the composition of Group I wherein B is a squalene synthase inhibitor.

Group III, claim 4, drawn to the composition of Group I wherein B is an inhibitor of HMG-CoA-reductase.

Group IV, claim 5, drawn to the composition of Group I wherein B is a clofibrin derivative.

Group V, claim 6, drawn to the composition of Group I wherein B is a bisphosphonic acid derivative.

Group VI, claim(s) 7-15 and 17, drawn to the composition of Group I wherein A is a phosphorus containing compound.

Group VII, claim(s) 16 and 18, drawn to the composition of Group I wherein A is an amide compound.

Art Unit: 1616

Group VIII, claim 19, drawn to the composition of Group I wherein A is a thiadiazole compound.

OK
(P in Z com. must)
Group IX, claim 20, drawn to the composition of Group I wherein A is an oxazole compound.

Group X, claim(s) 21-23, drawn to uses of lipid metabolism inhibitors for treating infectious processes in humans and animals.

Group XI, claim(s) 21-22, drawn to uses of lipid metabolism inhibitors for treating infectious processes in plants.

→ Group XII, claim 21, drawn to uses of lipid metabolism inhibitors as herbicides.

The inventions listed as Groups II-XII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the different components under A and B must be members of a recognized class of compounds, but instead represent a plurality of classes. See PCT Administrative Instructions, Annex B, Part 2, Example 23.

Applicant is required to elect:

one of Groups II-V (B component class)

one of Groups VI-IX (A component class)

one of Groups X-XII (utility)

Group I will be examined along with the elected Groups (elected A class, B class, and utility).

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1., as noted above.

Art Unit: 1616

The species are as follows: any combination of a specific pair of compounds from each of the A and B components as noted above.

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The following claim(s) are generic: 1, 2, 21.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to S. Mark Clardy whose telephone number is (703) 308-4550.



S. Mark Clardy
Primary Examiner
AU 1616

March 14, 2002